Tema ETFs’s Monte Rosa Therapeutics GLUE Stock Holding History

Tema ETFs’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-24,767	Closed	-$388K	–	579
2025 Q4	$388K	Buy	+24,767	New	+$334K	0.03%	405

Other funds holding GLUE

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Tema ETFs's GLUE Position: Q1 2026 in Review

Tema ETFs sold out of Monte Rosa Therapeutics (GLUE) in Q1 2026, closing a stake of 24,767 shares — an estimated $388K sold.

Tema ETFs first reported a position in GLUE in Q4 2025 and held it in 1 quarter. The position peaked at $388K in Q4 2025. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

Tema ETFs reported no remaining Monte Rosa Therapeutics position as of Q1 2026 after selling out during the quarter.
Tema ETFs sold 24,767 Monte Rosa Therapeutics shares in Q1 2026, an estimated $388K.
Tema ETFs first reported a position in Monte Rosa Therapeutics in Q4 2025 and held it in 1 quarter.
Tema ETFs's Monte Rosa Therapeutics position peaked at $388K in Q4 2025.
190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Tema ETFs's 13F filing for Q1 2026, filed 15 Apr 2026.